This FDA final guidance (December 2024) establishes the regulatory framework for Predetermined Change Control Plans (PCCPs) enabling efficient modification management for AI-enabled medical device software. The PCCP mechanism, authorized under FDORA Section 515C, permits manufacturers to implement specified software modifications without submitting supplemental premarket applications, provided modifications remain within the FDA-approved change control plan. Manufacturers must establish comprehensive PCCPs describing anticipated modification categories, methodologies for implementing changes while maintaining safety and effectiveness, and impact assessment procedures demonstrating that modifications do not adversely affect device performance or patient safety. Each PCCP submission must include three essential elements: clear descriptions of modifications covered by the plan, detailed methodologies and procedures for implementing modifications, and systematic impact assessment approaches demonstrating continued compliance with original approval specifications. The guidance specifies that PCCPs must align with 21 CFR Part 820 (Quality Management System Regulation) change management requirements, ensuring integration within broader quality system frameworks. This mechanism substantially reduces regulatory burden while maintaining robust oversight of AI algorithm modifications. Manufacturers should carefully define PCCP scope to encompass anticipated algorithm refinements while excluding modifications requiring comprehensive re-validation.